Last reviewed · How we verify
Lactobacillus brevis CD2 Lozenges
Lactobacillus brevis CD2 is a probiotic lozenge that colonizes the oral and respiratory tract to modulate local and systemic immune responses.
Lactobacillus brevis CD2 is a probiotic lozenge that colonizes the oral and respiratory tract to modulate local and systemic immune responses. Used for Respiratory tract infections (prevention or treatment), Oral health / periodontal disease.
At a glance
| Generic name | Lactobacillus brevis CD2 Lozenges |
|---|---|
| Also known as | Probiotics |
| Sponsor | Next Gen Pharma India Pvt. Ltd. |
| Drug class | Live biotherapeutic product (probiotic) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This live biotherapeutic product delivers viable Lactobacillus brevis CD2 bacteria via oral lozenge formulation, allowing direct contact with oral mucosa and subsequent colonization of the respiratory tract. The mechanism involves stimulation of innate and adaptive immune responses through pattern recognition receptors, enhancement of barrier function, and production of antimicrobial compounds and immunomodulatory metabolites.
Approved indications
- Respiratory tract infections (prevention or treatment)
- Oral health / periodontal disease
Common side effects
- Gastrointestinal disturbance
- Oral irritation
- Allergic reaction
Key clinical trials
- L Brevis for Traumatic Oral Lesions in Orthodontic Patients (PHASE2)
- CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy (PHASE3)
- Effect of Probiotics on Chronic Periodontitis in Smoker and Non- Smokers (PHASE3)
- Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients (PHASE3)
- Effect of Probiotic Lozenge on Gingivitis and Periodontitis (PHASE3)
- Efficacy of a Probiotic Lozenges in Chronic Periodontitis Patients. (PHASE3)
- Probiotic Lozenge Reduce Streptococcus Mutans in Plaque in Orthodontic Bracket Patients (PHASE3)
- Effect of Probiotic Inersan and Doxycycline in Chronic Periodontitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactobacillus brevis CD2 Lozenges CI brief — competitive landscape report
- Lactobacillus brevis CD2 Lozenges updates RSS · CI watch RSS
- Next Gen Pharma India Pvt. Ltd. portfolio CI